CureVac (CVAC) has released an update.
CureVac has commenced a Phase 2 study of its updated mRNA-based multivalent seasonal influenza vaccine, developed with GSK, to enhance immune responses, particularly against influenza B strains. The revised vaccine candidate now aligns with WHO recommendations, targeting three specific flu strains. The study, involving 500 participants across different age groups, aims to compare the vaccine’s safety and efficacy with licensed comparator vaccines.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
